002793.SZ
002793.SZ
CNE1000026S7
LUOXINPHARMACEUTICAL
Loading chart...
Elevated Business & Solvency Risk

Caution: In addition to price volatility, there are balance sheet risks due to higher debt or weaker liquidity (Health Score: 42/100).

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.3x).

Beta (Market Relation)
0.26x
Defensive
Volatility (5Y p.a.)
46.2% p.a.
5-Year Horizon
Max Drawdown (5Y)
-70.2%
5-Year Horizon
Sharpe Ratio
-0.34
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -0.2%
3 Years 47.6% -45.8% -0.13 -3.5%
5 Years 46.2% -70.2% -0.34 -12.2%
10 Years 47.0% -87.4% -0.31 -11.9%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (46.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -87.4% in the extended horizon.
ende